Remembering Patrick Swayze

Article

The news of Patrick Swayze's death on Monday night was unexpected, but not shocking. Pancreatic cancer is such a horrible disease, with a five-year survival rate of only 5 percent. The fact that he was able to work throughout much of his treatment and lived for nearly two years after his diagnosis is a silver-lining to this sad ending.Swayze's death will certainly put pancreatic cancer more on the public radar, something this rare, but deadly disease is often lacking--awareness and funding for research. The Pancreatic Action Network, the national non-profit organization dedicated to ending pancreatic cancer, noted that although more than 42,000 people will be diagnosed and more than 35,000 will die each year of the disease, it is still "the most under-funded among leading cancer killers with less than 2 percent of the National Cancer Institute's annual research budget--a figure far too low given the severity of the disease."Swayze did much to raise awareness of the disease and fought for increased spending for cancer research. In February, he penned a piece in the Washington Post, "I'm Battling Cancer. How About Some Help, Congress?" where he made a case for increased cancer research funding for the National Institutes of Health as part of the economic stimulus package. And he appeared in the September 2008 TV event "Stand Up to Cancer," where he said: "I keep dreaming of a future, a future with a long and healthy life, a life not lived in the shadow of cancer, but in the light. ... I dream that the word `cure' will no longer be followed by the words 'it is impossible. ... The longer we do nothing, the more people will die.' "Thank you, Patrick, for the memories and your legacy as a cancer survivor.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content